Search

everythinglearnresearchcommunity

for

Search:↓

The user started a hair care routine using 0.5mg finasteride daily, 2ml of 5% minoxidil, and 4.5mg of cetirizine topically to address hair loss. They plan to provide updates and are also interested in cetirizine's potential to reduce scalp itching and redness due to its anti-inflammatory properties.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.

A user reports positive results with finasteride, noticing thicker hair and regrowth at the temples and hairline. Another user shares their experience with minoxidil, noting small hairs that haven't grown, and plans to add finasteride to their regimen.

A 30-year-old male is considering finasteride or a hair transplant for hairline recovery after 3 months of using Minoxidil foam without seeing regrowth. Another user advises against a hair transplant, suggesting it's too early.

Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

The user experienced improved self-confidence and hair regrowth using finasteride, minoxidil, and dermarolling. Visible results were noted after about three months, with microneedling done once a week.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

User discusses hair regrowth using RU58841, minoxidil, and dutasteride. Many users praise the progress and ask about the treatments' effectiveness and side effects.

The user has seen positive results after 16 months of using topical Finasteride/Minoxidil, microneedling weekly, and Tretinoin for hair loss. There are no reported side effects, and the user advises that the effectiveness of microneedling depends on the pressure applied.

The user is experiencing hair loss and is using treatments like finasteride, minoxidil, and hormone replacement therapy (estradiol enanthate injections) to address it. They are advised to be patient with the treatments and consider using a dermapen for microneedling.

The user reports noticeable hair regrowth after three months using 1mg finasteride daily, 5% topical minoxidil twice a day, and 0.25mm microneedling twice a week. They experienced significant shedding initially.

JeremySoCa's DHT level was 29 ng/dl, considered low, and Estradiol was 26.1 pg/dl within the normal range. They are using topical finasteride for hair loss and had a thyroidectomy due to Graves' disease.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.

The user has been using finasteride for 15 months, minoxidil for 4.5 months, and estrogen monotherapy for 4.5 months. Their current regimen includes finasteride, minoxidil, alfatradiol, and estradiol gel.

The user reported progress in hair regrowth after three months of using oral finasteride and minoxidil foam, despite initial doubts. They noted no side effects, a clean diet, regular weightlifting, and additional supplements.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

A 19-year-old trans female has been using topical minoxidil and dermarolling for nearly two months, alongside oral minoxidil, finasteride, spironolactone, and estrogen. She noticed significant hair improvement after starting topical minoxidil and dermarolling.

A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.

A man shared his 4-month progress using finasteride, minoxidil, and microneedling for hair loss treatment. He experienced positive results without side effects, and plans to continue the regimen.

User reports 2-month progress using Fin, Min, and microneedling for hair regrowth. Mixed opinions on results, some skeptical of fast growth, others encouraging and recommending Fin for stable results.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

The user is experiencing hair regrowth using topical 0.3% finasteride and 6% minoxidil, with no side effects noted. They are considering switching to oral treatments if progress stalls, but are currently satisfied with the results.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.